Method of treating delayed healing of a wound associated with diabetes

Abstract

The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

We claim: 
     
         1 . A method of treating delayed healing of a wound associated with diabetes, comprising the step of administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. 
     
     
         2 . The method of treating delayed healing of a wound according to  claim 1 , wherein the anti-senescence compound is selected from the group consisting of 18α-Glycyrrhetinic acid, a Cav-1 inhibitory compound, and a PTRF-1 inhibitory compound. 
     
     
         3 . The method of treating delayed healing of a wound associated with diabetes as recited in  claim 1 , wherein the anti-senescence compound comprises an antisense oligonucleotide for inhibiting expression of Cav-1. 
     
     
         4 . The method of treating delayed healing of a wound associated with diabetes—as recited in  claim 3 , wherein the antisense oligonucleotide is a Morpholino antisense oligonucleotide. 
     
     
         5 . The method of treating delayed healing of a wound associated with diabetes as recited in  claim 1 , wherein the anti-senescence compound comprises an siRNA for inhibiting expression of Cav-1. 
     
     
         6 . The method of treating delayed healing of a wound associated with diabetes—as recited in  claim 1 , wherein the anti-senescence compound comprises an antisense oligonucleotide for inhibiting expression of PTRF-1. 
     
     
         7 . The method of treating delayed healing of a wound associated with diabetes—as recited in  claim 6 , wherein the antisense oligonucleotide is a Morpholino antisense oligonucleotide. 
     
     
         8 . The method of treating delayed healing of a wound associated with diabetes—as recited in  claim 1 , wherein the pharmaceutically acceptable carrier comprises pluronic acid. 
     
     
         9 . The method of treating delayed healing of a wound associated with diabetes—as recited in  claim 1 , wherein the anti-senescence compound is present in a concentration range of 30 μM to 100 μM. 
     
     
         10 . The method of treating delayed healing of a wound associated with diabetes—as recited in  claim 1 , wherein the wound is a diabetic ulcer. 
     
     
         11 . The method of treating delayed healing of a wound associated with diabetes—as recited in  claim 1 , wherein the wound is a venous ulcer. 
     
     
         12 . The method of treating delayed healing of a wound according to  claim 1 , wherein the anti-senescence compound comprises 18α-Glycyrrhetinic acid.